Bosentan Hydrate
Tier C — Watch / tradeBosentan Hydrate
Targets:ETAR, ETBR
Brand:Tracleer, Stayveer
Indications (approved):溃疡, Pulmonary arterial hypertension, Pulmonary hypertension, Systemic sclerosis
Regional status
Synthetic routes & intermediates5 routes
Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.
| Code | CAS No. | Intermediate |
|---|---|---|
| BOSE-001 | 90-05-1 | 2-methoxyphenol |
| BOSE-002 | 685-87-0 | diethyl 2-bromomalonate |
| BOSE-003 | 20730-58-9 | diethyl 2-(2-methoxyphenoxy)malonate |
| BOSE-004 | - | pyrimidine-2-carboximidamide hydrochloride |
| BOSE-005 | 329923-15-1 | 5-(2-methoxyphenoxy)-[2,2'-bipyrimidine]-4,6-diol |
| BOSE-006 | 150728-13-5 | 4,6-dichloro-5-(2-methoxyphenoxy)-2,2'-bipyrimidine |
| BOSE-007 | 6292-59-7 | 4-(tert-butyl)benzenesulfonamide |
| BOSE-008 | 150727-06-3 | 4-(tert-butyl)-N-(6-chloro-5-(2-methoxyphenoxy)-[2,2'-bipyrimidin]-4-yl)benzenesulfonamide |
| BOSE-009 | 107-21-1Available | ethane-1,2-diol |
| Code | CAS No. | Intermediate |
|---|---|---|
| BOSE-006 | 150728-13-5 | 4,6-dichloro-5-(2-methoxyphenoxy)-2,2'-bipyrimidine |
| BOSE-007 | 6292-59-7 | 4-(tert-butyl)benzenesulfonamide |
| BOSE-010 | 2162-31-4 | 2-((tetrahydro-2H-pyran-2-yl)oxy)ethan-1-ol |
| BOSE-011 | - | 4-chloro-5-(2-methoxyphenoxy)-6-(2-((tetrahydro-2H-pyran-2-yl)oxy)ethoxy)-2,2'-bipyrimidine |
| BOSE-012 | - | 4-(tert-butyl)-N-(5-(2-methoxyphenoxy)-6-(2-((tetrahydro-2H-pyran-2-yl)oxy)ethoxy)-[2,2'-bipyrimidin]-4-yl)benzenesulfonamide |
| Code | CAS No. | Intermediate |
|---|---|---|
| BOSE-006 | 150728-13-5 | 4,6-dichloro-5-(2-methoxyphenoxy)-2,2'-bipyrimidine |
| BOSE-007 | 6292-59-7 | 4-(tert-butyl)benzenesulfonamide |
| BOSE-013 | 150728-12-4 | 5-(2-methoxyphenoxy)-[2,2'-bipyrimidine]-4,6(1H,5H)-dione |
| BOSE-014 | - | potassium ((4-(tert-butyl)phenyl)sulfonyl)(6-chloro-5-(2-methoxyphenoxy)-[2,2'-bipyrimidin]-4-yl)amide |
| BOSE-018 | 14080-23-0 | pyrimidine-2-carbonitrile |
| BOSE-019 | 150726-89-9 | dimethyl 2-(2-methoxyphenoxy)malonate |
| BOSE-020 | 621-63-6 | 2,2-diethoxyethan-1-ol |
| BOSE-021 | 1250871-99-8 | 4-(tert-butyl)-N-(6-(2,2-diethoxyethoxy)-5-(2-methoxyphenoxy)-[2,2'-bipyrimidin]-4-yl)benzenesulfonamide |
| BOSE-022 | 1174918-30-9 | 4-(tert-butyl)-N-(5-(2-methoxyphenoxy)-6-(2-oxoethoxy)-[2,2'-bipyrimidin]-4-yl)benzenesulfonamide |
| Code | CAS No. | Intermediate |
|---|---|---|
| BOSE-006 | 150728-13-5 | 4,6-dichloro-5-(2-methoxyphenoxy)-2,2'-bipyrimidine |
| BOSE-007 | 6292-59-7 | 4-(tert-butyl)benzenesulfonamide |
| BOSE-008 | 150727-06-3 | 4-(tert-butyl)-N-(6-chloro-5-(2-methoxyphenoxy)-[2,2'-bipyrimidin]-4-yl)benzenesulfonamide |
| BOSE-022 | 1174918-30-9 | 4-(tert-butyl)-N-(5-(2-methoxyphenoxy)-6-(2-oxoethoxy)-[2,2'-bipyrimidin]-4-yl)benzenesulfonamide |
| BOSE-023 | - | (2,2-dimethyl-1,3-dioxolane-4,5-diyl)dimethanol |
| BOSE-024 | 1448588-52-0 | N,N'-((((2,2-dimethyl-1,3-dioxolane-4,5-diyl)bis(methylene))bis(oxy))bis(5-(2-methoxyphenoxy)-[2,2'-bipyrimidine]-6,4-diyl))bis(4-(tert-butyl)benzenesulfonamide) |
| BOSE-025 | 1448588-53-1 | N,N'-(((2,3-dihydroxybutane-1,4-diyl)bis(oxy))bis(5-(2-methoxyphenoxy)-[2,2'-bipyrimidine]-6,4-diyl))bis(4-(tert-butyl)benzenesulfonamide) |
| Code | CAS No. | Intermediate |
|---|---|---|
| BOSE-006 | 150728-13-5 | 4,6-dichloro-5-(2-methoxyphenoxy)-2,2'-bipyrimidine |
| BOSE-007 | 6292-59-7 | 4-(tert-butyl)benzenesulfonamide |
| BOSE-013 | 150728-12-4 | 5-(2-methoxyphenoxy)-[2,2'-bipyrimidine]-4,6(1H,5H)-dione |
| BOSE-014 | - | potassium ((4-(tert-butyl)phenyl)sulfonyl)(6-chloro-5-(2-methoxyphenoxy)-[2,2'-bipyrimidin]-4-yl)amide |
| BOSE-015 | 7580-85-0 | 2-(tert-butoxy)ethanol |
| BOSE-016 | - | N-(6-(2-(tert-butoxy)ethoxy)-5-(2-methoxyphenoxy)-[2,2'-bipyrimidin]-4-yl)-4-(tert-butyl)benzenesulfonamide |
| BOSE-017 | - | 2-((6-((4-(tert-butyl)phenyl)sulfonamido)-5-(2-methoxyphenoxy)-[2,2'-bipyrimidin]-4-yl)oxy)ethyl formate |
Frequently asked questions
What are the approved indications of Bosentan Hydrate?
Approved indications include: 溃疡, Pulmonary arterial hypertension, Pulmonary hypertension, Systemic sclerosis.
When does the Bosentan Hydrate patent expire?
No public expiry year is available for Bosentan Hydrate yet; this page updates once verified.
How many synthesis routes are recorded for Bosentan Hydrate?
5 synthesis routes are recorded; the shortest is 3 steps with 107 mg total yield. Intermediates in each route carry codes and CAS numbers.
Where can I buy Bosentan Hydrate intermediates?
1 intermediate CAS of Bosentan Hydrate are available through the Unibest supply network — see the route tables on this page and request a quote per CAS.
How do I get a quote for Bosentan Hydrate intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-27